A Trial Investigating the Pharmacodynamic Properties of NN5401 in Subjects With Type 1 Diabetes

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 30, 2012

Primary Completion Date

June 30, 2012

Study Completion Date

June 30, 2012

Conditions

DiabetesDiabetes Mellitus, Type 1

Interventions

DRUG

insulin degludec

Administered subcutaneously (s.c., under the skin) once daily (plus insulin aspart as bolus insulin as required).

DRUG

insulin degludec/insulin aspart

Single dose administered subcutaneously (s.c., under the skin).

Trial Locations (1)

Novo Nordisk Investigational Site, Neuss